Does lapatinib work against HER2-negative breast cancers?

Mayer IA, Arteaga CL
Clin Cancer Res. 2010 16 (5): 1355-7

PMID: 20179241 · PMCID: PMC3448974 · DOI:10.1158/1078-0432.CCR-09-3223

Aberrant growth factor receptor signaling can augment or suppress estrogen receptor (ER) function in hormone-dependent breast cancer cells and lead to escape from anti-estrogen therapy. Interruption of HER2/ER cross-talk with lapatinib can restore sensitivity to anti-estrogens and thus, should be investigated in combination with endocrine therapy in patients with ER+/HER2-negative breast cancers.

MeSH Terms (12)

Animals Antineoplastic Agents Breast Neoplasms Clinical Trials as Topic Drug Resistance, Neoplasm Female Humans Lapatinib Quinazolines Receptor, ErbB-2 Receptor Cross-Talk Receptors, Estrogen

Connections (1)

This publication is referenced by other Labnodes entities: